Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.98 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.98 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | RHOC | P08134 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | THRB | P10828 | 1/20 | 0.98 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.98 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.86 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.86 |
| ▸ | PDE6D | O43924 | 3/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL3831 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL537781 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL4201645 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3056792 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL465015 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL8257670 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL13900412 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL6266705 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL21637576 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL5077146 | 0.98 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648109-B2 | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium | WARNER-LAMBERT COMPANY LLC (US) | 2014-02-11 | — | — | US | claimed |
| CN-103340852-A | Pharmaceutical composition containing ezetimibe and atorvastatin | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-10-09 | — | — | CN | claimed |
| US-20130131138-A1 | NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b,d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID MAGNESIUM | WARNER-LAMBERT COMPANY LLC (US) | 2013-05-23 | — | — | US | claimed |
| US-8383667-B2 | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium | WARNER LAMBERT LLC (US) | 2013-02-26 | — | — | US | claimed |
| US-20120059040-A1 | NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID MAGNESIUM | PFIZER INC | 2012-03-08 | — | — | US | claimed |
| US-8084488-B2 | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium | PFIZER INC. (US) | 2011-12-27 | — | — | US | claimed |
| US-20110142883-A1 | Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts | ACTAVIS GROUP PTC EHF (IS) | 2011-06-16 | — | — | US | claimed |
| CN-102018708-A | Pharmaceutical composition containing amlodipine and atorvastatin magnesium | FEI LIN | 2011-04-20 | — | — | CN | claimed |
| CN-101991853-A | Statin magnesium-containing blood lipid lowering composition | BEIJING LILESHENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-03-30 | — | — | CN | claimed |
| CN-101991854-A | Novel blood fat-lowering composition | BEIJING LILESHENG PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-03-30 | — | — | CN | claimed |
| EP-1818049-A2 | Stabilized Atorvastatin | LifeCycle Pharma A/S (DK) | 2007-08-15 | — | — | EP | claimed |
| WO-2007063551-A1 | POLYMORPHS OF [R-(R*, R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(l-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-lH-PYRROLE-l-HEPTANOIC ACID MAGNESIUM SALT (2: 1) | BIOCON LIMITED (IN) | 2007-06-07 | — | — | WO | claimed |
| WO-2007057755-A1 | NOVEL FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-B,B-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPT ANOIC ACID MAGNESIUM | WARNER-LAMBERT COMPANY LLC (US) | 2007-05-24 | — | — | WO | claimed |
| CN-1911213-A | Soft capsule of atovastatine salts and prepn. method therefor | OUYI PHARMACEUTICAL CO LTD SHI (CN) | 2007-02-14 | — | — | CN | claimed |
| WO-2006117761-A2 | MAGNESIUM SALTS OF HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| WO-2006084474-A2 | A STABLE PHARMACEUTICAL COMPOSITION COMPRISING A FIXED DOSE COMBINATION OF FENOFIBRATE AND AN HMG-COA REDUCTASE INHIBITOR | LIFECYCLE PHARMA A/S (DK) | 2006-08-17 | — | — | WO | claimed |
| CN-1642526-A | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LAB LTD (IN) | 2005-07-20 | — | — | CN | claimed |
| US-20030175338-A1 | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LABORTORIES LIMITED (IN) | 2003-09-18 | — | — | US | claimed |
| WO-2003068191-A1 | FORMULATIONS OF ATORVASTATIN STABILIZED WITH ALKALI METAL ADDITIONS | RANBAXY LABORATORIES LIMITED (IN) | 2003-08-21 | — | — | WO | claimed |
| EP-1336405-A1 | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LABORATORIES, LTD. (IN) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142883-A1 | Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts | HMGCR, CETP, NPC1L1 | HMGCR 1/4885SLCO1B1 38/4885ABCB11 125/4885 |
| US-20030175338-A1 | Formulations of atorvastatin stabilized with alkali metal additions | APOB, HMGCR, SLC10A1 | HMGCR 2/4885SLCO1B1 63/4885ABCB11 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.